|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン（シャンハイ）コーポレイション リミテッド |
多重特異性Ｆａｂ融合タンパク質および使用法
|
|
CA2844540C
(en)
|
2011-08-23 |
2018-10-16 |
Roche Glycart Ag |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
CN104704004B
(zh)
|
2012-10-08 |
2019-12-31 |
罗切格利卡特公司 |
包含两个Fab片段的无Fc的抗体及使用方法
|
|
EA031214B1
(ru)
|
2013-02-26 |
2018-12-28 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
|
EP2789630A1
(en)
*
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
|
CN106661120B
(zh)
|
2014-08-04 |
2021-10-01 |
豪夫迈·罗氏有限公司 |
双特异性t细胞活化性抗原结合分子
|
|
PT3221357T
(pt)
|
2014-11-20 |
2020-07-28 |
Hoffmann La Roche |
Cadeias leves comuns e métodos de utilização
|
|
JP6944369B2
(ja)
|
2014-11-20 |
2021-10-06 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔ細胞活性化二重特異性抗原結合分子ｃｄ３ ａｂｄ葉酸受容体１（ｆｏｌｒ１）及びｐｄ−１軸結合アンタゴニストの併用療法
|
|
MA40972B1
(fr)
|
2014-11-20 |
2020-11-30 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
MA43025A
(fr)
|
2015-10-02 |
2021-05-26 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t anti-ceaxcd3
|
|
AU2016345681A1
(en)
|
2015-10-30 |
2018-05-10 |
Nbe-Therapeutics Ag |
Anti-ROR1 antibodies
|
|
PL3387015T3
(pl)
|
2015-12-09 |
2022-02-14 |
F. Hoffmann-La Roche Ag |
Przeciwciało anty-CD20 typu II do ograniczania tworzenia przeciwciał przeciwlekowych
|
|
JP6949030B2
(ja)
|
2016-01-08 |
2021-10-13 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Ｐｄ−１軸結合アンタゴニスト及び抗ｃｅａ／抗ｃｄ３二重特異性抗体を用いたｃｅａ陽性がんの治療方法
|
|
KR20180101554A
(ko)
|
2016-01-20 |
2018-09-12 |
더 스크립스 리서치 인스티튜트 |
Ｒｏｒ１ 항체 조성물 및 관련 방법
|
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
RS64266B1
(sr)
|
2016-03-22 |
2023-07-31 |
Hoffmann La Roche |
Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
|
|
ES2897217T3
(es)
|
2016-09-30 |
2022-02-28 |
Hoffmann La Roche |
Anticuerpos biespecíficos frente a p95HER2
|
|
EP3619235A1
(en)
*
|
2017-04-11 |
2020-03-11 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
AU2018289581C1
(en)
|
2017-06-23 |
2025-01-30 |
VelosBio Inc. |
ROR1 antibody immunoconjugates
|
|
GB201710838D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
Bispecific antibodies
|
|
GB201710836D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Car T-Cells
|
|
GB201710835D0
(en)
|
2017-07-05 |
2017-08-16 |
Ucl Business Plc |
ROR1 Antibodies
|
|
WO2019016381A1
(en)
*
|
2017-07-20 |
2019-01-24 |
Nbe-Therapeutics Ag |
MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
|
|
EP3665193A1
(en)
|
2017-08-07 |
2020-06-17 |
NBE Therapeutics AG |
Anthracycline-based antibody drug conjugates having high in vivo tolerability
|
|
CN107827984B
(zh)
*
|
2017-09-13 |
2021-03-16 |
张慧林 |
嵌合抗ROR1抗体Fab分子及其制备方法和应用
|
|
GB201721802D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Almac Discovery Ltd |
Ror1-specific antigen binding molecules
|
|
CA3089287A1
(en)
|
2018-02-08 |
2019-08-15 |
Genentech, Inc. |
Bispecific antigen-binding molecules and methods of use
|
|
TWI829667B
(zh)
*
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
AR115320A1
(es)
|
2018-03-30 |
2020-12-23 |
Merus Nv |
Anticuerpo multivalente
|
|
SG11202009804RA
(en)
|
2018-04-11 |
2020-11-27 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
CN112384533A
(zh)
*
|
2018-04-18 |
2021-02-19 |
埃克塞里艾克西斯公司 |
抗-ror抗体构建体
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
EP3847196A4
(en)
*
|
2018-09-07 |
2023-01-04 |
ITabMed (HK) Limited |
BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
|
|
US20210340273A1
(en)
*
|
2018-10-11 |
2021-11-04 |
Inhlbrx, inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
|
CA3115089A1
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
|
EP3986925A1
(en)
*
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
|
BR112022001460A2
(pt)
*
|
2019-07-31 |
2022-03-22 |
Hoffmann La Roche |
Moléculas de ligação ao antígeno biespecíficas, um ou mais polinucleotídeos isolados, célula hospedeira, método para produzir uma molécula de ligação ao antígeno biespecífica e para tratar uma doença em um indivíduo, composição farmacêutica, uso da molécula de ligação ao antígeno biespecífica e invenção
|
|
BR112022014667A2
(pt)
|
2020-01-29 |
2022-09-20 |
Inhibrx Inc |
Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
|
|
BR112022025856A2
(pt)
|
2020-06-19 |
2023-01-10 |
Hoffmann La Roche |
Anticorpo que se liga a cd3 e cd19, polinucleotídeo isolado, célula hospedeira, método de produção de um anticorpo que se liga a cd3 e cd19, composição farmacêutica, uso do anticorpo, método para tratar uma doença em um indivíduo e invenção
|
|
JP7781859B2
(ja)
*
|
2020-08-24 |
2025-12-08 |
エピムアブ、バイオセラピューティクス、（ホンコン）、リミテッド |
抗ｒｏｒ１抗体及び関連の二重特異性結合タンパク質
|
|
EP3988568A1
(en)
*
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
CA3203831A1
(en)
*
|
2020-12-29 |
2022-07-07 |
Dongheon Lee |
Bi- or multi-specific antibody
|
|
CA3208781A1
(en)
*
|
2021-02-02 |
2022-08-11 |
Bithi CHATTERJEE |
Multispecific antibodies having specificity for ror1 and cd3
|
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
|
AU2024225436A1
(en)
*
|
2023-02-23 |
2025-08-28 |
Adanate, Inc. |
Anti-cd3 antibodies and methods for their use
|